Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$84.62 +3.1%	$88.95	$73.04 ▼ $121.90	$5.41B	0.75	768,669 shs	634,400 shs
INDV Indivior	$9.01 -0.6%	$9.52	$7.33 ▼ $19.13	$1.24B	0.93	941,286 shs	1.48 million shs
SRPT Sarepta Therapeutics	$53.79 -0.3%	$83.33	$48.01 ▼ $173.25	$5.22B	0.93	1.41 million shs	1.91 million shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$16.71 +1.0%	$17.24	$13.61 ▼ $30.36	$5.64B	N/A	27,369 shs	8,472 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	+3.06%	+5.42%	-5.54%	-23.10%	-4.25%
INDV Indivior	-0.55%	+0.78%	-7.49%	-22.66%	-53.22%
SRPT Sarepta Therapeutics	-0.28%	+6.92%	-26.86%	-54.42%	-54.37%
TLX Telix Pharmaceuticals Limited American Depositary Shares	+1.03%	+1.89%	-3.41%	-0.42%	+1,670,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	2.6722 of 5 stars	4.3	1.0	0.0	0.0	3.3	0.8	0.6
INDV Indivior	3.7522 of 5 stars	3.6	5.0	0.0	0.0	2.9	1.7	1.9
SRPT Sarepta Therapeutics	4.6739 of 5 stars	4.4	2.0	0.0	4.2	2.9	2.5	1.9
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.70	Moderate Buy	$124.95	47.65% Upside
INDV Indivior	3.25	Buy	$15.00	66.48% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$161.83	200.85% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	31.66% Upside

Current Analyst Ratings Breakdown

Latest INDV, BPMC, SRPT, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/16/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$75.00 ➝ $75.00
4/11/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$196.00 ➝ $182.00
4/11/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$115.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
4/3/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$202.00 ➝ $183.00
4/2/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$75.00 ➝ $75.00
3/31/2025	SRPT Sarepta Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$161.00 ➝ $87.00
3/20/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$120.00 ➝ $100.00
3/20/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$105.00 ➝ $80.00
3/19/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$124.00 ➝ $99.00

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	10.63	N/A	N/A	$4.67 per share	18.12
INDV Indivior	$1.19B	1.05	$1.82 per share	4.94	N/A	∞
SRPT Sarepta Therapeutics	$1.90B	2.74	N/A	N/A	$9.19 per share	5.85
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.21	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$1.08	N/A	130.19	N/A	-13.19%	-77.49%	-20.84%	5/1/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	5.27	N/A	-3.96%	-241.73%	15.09%	4/24/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	$2.28	43.03	4.92	N/A	7.43%	11.00%	3.35%	4/29/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	34.81	N/A	N/A	N/A	N/A	N/A

Latest INDV, BPMC, SRPT, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	N/A	N/A	N/A	$685.75 million	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.44	N/A	N/A	N/A	$158.31 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	N/A	N/A	N/A	$240.13 million	N/A
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
INDV Indivior	N/A	0.83	0.65
SRPT Sarepta Therapeutics	0.93	3.84	3.03
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
INDV Indivior	60.33%
SRPT Sarepta Therapeutics	86.68%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
INDV Indivior	N/A
SRPT Sarepta Therapeutics	7.70%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	63.91 million	61.22 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
SRPT Sarepta Therapeutics	840	97.03 million	88.17 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.71 million	N/A	N/A

INDV, BPMC, SRPT, and TLX Headlines

Recent News About These Companies

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

April 15 at 6:37 PM | globenewswire.com

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

April 14, 2025 | zacks.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 1.4% - Here's Why

April 9, 2025 | marketbeat.com

Telix Shares May Gain on the Distribution Deal With Cardinal Health

April 9, 2025 | zacks.com

Telix Announces Cardinal Health for Gozellix Commercial Distribution

April 8, 2025 | globenewswire.com

Telix Appoints Paul Schaffer as Chief Technology Officer

April 7, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sets New 52-Week Low - Time to Sell?

April 7, 2025 | marketbeat.com

Telix Pharmaceuticals expects no 'material impact' from tariffs

April 7, 2025 | msn.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sees Strong Trading Volume - Should You Buy?

April 6, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?

April 4, 2025 | marketbeat.com

Anne Whitaker Appointed as Non-Executive Director

April 3, 2025 | globenewswire.com

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

April 1, 2025 | globenewswire.com

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

April 1, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Down 4.4% - Here's What Happened

March 28, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Up 4.4% - Should You Buy?

March 22, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?

March 21, 2025 | marketbeat.com

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

March 21, 2025 | investopedia.com

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

March 21, 2025 | globenewswire.com

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

March 17, 2025 | globenewswire.com

Telix Adds Lead-212 Isotope Production Capability

March 12, 2025 | globenewswire.com

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

March 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV, BPMC, SRPT, and TLX Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$84.62 +2.51 (+3.06%)

Closing price 04/17/2025 03:59 PM Eastern

Extended Trading

$81.91 -2.71 (-3.21%)

As of 04/17/2025 04:42 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Indivior NASDAQ:INDV

$9.01 -0.05 (-0.55%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$9.01 0.00 (-0.06%)

As of 04/17/2025 05:44 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Sarepta Therapeutics NASDAQ:SRPT

$53.79 -0.15 (-0.28%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$54.43 +0.64 (+1.18%)

As of 04/17/2025 05:51 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$16.71 +0.17 (+1.03%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$17.20 +0.49 (+2.93%)

As of 04/17/2025 05:58 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time